About

“ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical. #oligo #mRNA #CDMO #smallmolecule #CMO #rawmaterials About ST Pharm “ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical. #oligo #mRNA #gRNA #sgRNA #CDMO #smallmolecule #CMO #rawmaterials #LNP #Capping #conjugation About ST Pharm “ST Pharm provides reliable and timely custom manufacturing services for API following stringent quality system and close communication with the clients.” Founded in 1983, ST Pharm (formerly known as Samchully Pharmaceutical) has been offering excellent custom manufacturing services of APIs and their intermediates to meet clients’ high expectation for their use in pharmaceutical development in compliant to cGMP requirements. Our reliability in service, which is well-proven through decades of business relationship with many big pharmas and biotech clients, is the essence of our strength along with our expertise in process development and scale-up optimization. Historically, ST Pharm has been focusing our expertise on nucleoside based active pharmaceuticals in various antiviral drug applications; we became the world largest supplier of Thymidine in the late 1990s and Zidovudine in the mid 2000s and protected nucleosides in the early 2000s. ST Pharm has continuously been expanding its service offering, including synthesis of therapeutic oligonucleotides. In June 2010, ST Pharm became a subsidiary of Dong-A Pharmaceutical, the top pharmaceutical company in Korea. ST Pharm is committed to expanding its business scope into generic APIs and their intermediates with full support and collaboration with parent company Dong-A Pharmaceutical. #oligo #mRNA #gRNA #sgRNA #CDMO #smallmolecule #CMO #rawmaterials #LNP #Capping #conjugation ST PHARM Co., Ltd. (“ST PHARM”) is a Contract Development and Manufacturing Organization (CDMO) providing phase-appropriate development and manufacturing services for APIs, intermediates, and target compounds to global pharmaceutical and biotech clients. It operates two cGMP-certified facilities in Sihwa and Banwol, with a strong track record of regulatory audits by agencies such as the US FDA, EMA, PMDA, TGA, ANVISA, MFDS, and WHO. With decades of expertise, ST PHARM has been a trusted supplier of small molecule new chemical entity (NCE) target compounds for antiviral drugs, including HIV, HBV, and HCV. It is particularly recognized for its leadership in nucleoside/tide chemistry-based pharmaceuticals. Leveraging this expertise, ST PHARM entered the oligonucleotide CDMO business in the early 2000s. Now among the top three global CDMOs in this field, it successfully launched commercial oligonucleotide therapeutics in 2022, with multiple Pre-Approval Inspections (PAIs) scheduled for 2024 and 2025. ST PHARM has also developed proprietary materials such as SmartCap® (a 5'-capping analog) and STLNP® (ionizable lipids for LNP formulations), essential for mRNA therapeutics. These innovations are supporting the commercialization of mRNA-based drugs. Additionally, ST PHARM is expanding its capabilities in circular RNA (circRNA) manufacturing to drive next-generation RNA therapeutics.